Cellply
DeepTech startup developing analytical tools for characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics.
About
Cellply is a Bologna-based DeepTech startup focused on developing advanced analytical tools for the deep characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics. Their flagship product, VivaCyte®, is an automated analytical system that utilizes patented microfluidic technology, AI-powered image analysis, and dedicated software to enable rapid discovery and process development of cell therapies at single-cell resolution. The company aims to accelerate the adoption of Advanced Therapy Medicinal Products (ATMPs) by providing innovative quality control solutions that enhance potency and persistence, and streamline batch release and potency assays.
Key facts
At-a-glance profile data
- Headquarters
- Bologna, Italy
- Founded
- 2013
- Employees
- 25
- Total funding
- $7M (Funding Round)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 May 2026 | Funding Round | $7M | ENEA Tech e Biomedical |
Frequently asked
How much funding has Cellply raised?
Cellply has raised a total of $7M in funding. The most recent round on record is Funding Round.
How many employees does Cellply have?
Cellply has approximately 25 people on record.